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Experimental Procedures 
FACS analysis and microarray experiments 
To specifically isolate Olig2-expressing cells from E9.5-E12.5 embryos, an Olig2-GFP 
transgenic mouse (a gift from Ben Novitch) was utilized. Olig2-GFP mice were crossed 
with wild-type mice and embryos were isolated between E9.5-E12.5. Embryonic spinal 
cord was dissected out and dissociated with papain to generate a single-cell suspension, 
then sequentially incubated with anti-CD-15/MMA (monoclonal-IgM; Developmental 
Studies Hybridoma Studies-DSHB), then anti-PDGFRα (monoclonal-rat; BD 
Biosciences). PDGFRα-expressing cells were subtracted using a sheep-anti rat secondary 
antibody conjugated to magnetic beads and incubated on a magnetic column to eliminate 
cells reactive to PDGFRα antibody. FACS isolation was performed as described in 
(Mukouyama et al., 2006). 
 
For each timepoint, cells were harvested from at least two independent litters and pooled 
for FACS analysis. Replicate samples of each timepoint were independently generated, 
and processed in parallel. For microarray analysis, RNA from approximately 1x104 cells 
was isolated using the Stratagene Absolutely RNA-Nano Kit. Isolated RNA was 
subjected to two rounds of amplification using the Ambion MessageAmp kit (#1750). 
During the second round of amplification the cRNA was labeled using biotin-CTP and 
biotin-UTP. After cRNA amplification and labeling the product was fragmented and 
hybridized to Affymetrix arrays, mu74vA,B,C. Analysis of the microarray data was 
performed by Affeymetrix suite and the Rosetta Resolver system.  
 
 
Generation of RCAS/shRNAi 
To identify potential cNFIA sequences that could be used as an shRNAi, we used the 
Promega siRNA target designer and several other applications available on the web, in 
order to cross compare the sequences predicted by these different algorithms. The 
sequences that were identified by multiple programs were tested for silencing of cNFIA. 
The selected sequences were integrated into oligos containing a stem-loop sequence and 
sites to facilitate cloning. The format of the oligo design is as follows:  
Forward 5’ACC-----G(N20)------TTCAAGAGA------(20N)C-------TTTTTA 3’ 
Reverse  3’        -----C(N20)------AAGTTCTCT-------(20N)G--------AAAAAAGCTT  5’ 
Oligo’s were annealed, kinase treated and cloned into a Bluescript-hU6 plasmid (a gift 
from D. Baltimore) (Qin et al., 2003) Bbs1-HindIII. Clones were sequence verified, and 
the hU6-shRNAi cassette was shuttled into the Slax-12 vector (RI/Hind), then from Slax-
12 shuttled into RCAS(B) (Cla1). Orientation was confirmed via sequence analysis, hU6-
shRNAi was orientated with the 5’ hU6 orientated towards the 5’end of the RCAS 
5’LTR. RCAS-shRNAi constructs were electroporated into E2 chicks along with CMV-
GFP and collected at E6. Immunostaining with the avian retroviral coat protein, AMV, 
was used to confirm expression of RCAS-shRNAi. Embryos were then stained with 
antibodies to NFIA to asses whether a given shRNAi was successful in knocking down 
endogenous NFIA in the chick embryo. Of the four sequences tested one gave complete 
knockdown of NFIA. The sequence to cNFIA that yielded complete knockdown of 
endogenous protein and the mutant version are: 
GCCATCGCCAACTGCATTAAA  cNFIA-RNAi 
GCGATCTCCAACTACATTAAC cNFAI-RNAi mutant 
 
In Situ Hybridization and Immunohistochemistry 
Non-radioactive in situ hybridization on frozen mouse and chicken embryos was 
performed as previously described (Zhou et al., 2000). Mouse and chick tissue was fixed 
in 4% paraformaldehyde from 1 hour to overnight, depending upon the age of the 
embryo. The following probes were used for in situ hybridization: cGLAST, cFGFR3, 
cPDGFRα, mNFIA, mNFIB, mGLAST, and cHES5.  
 
Immunohistochemistry was performed on mouse and chicken embryonic tissue fixed as 
described above. The following antibodies, were used: hOlig2 (goat polyclonal), cOlig2 
(rb/polyclonal-gift from T. Jessell), bovine-GFAP (rabbit-polyclonal/DAKO), m-GFAP 
(mouse IgG1/Chemicon), ms100β (mouse-monoclonal-IgG1/Sigma), hNFIA (rabbit 
polyclonal/Geneka), hNFIB (rabbit polyclonal), AMV (mouse monoclonal-IgG1, 
DSHB), mSox9 (mouse monoclonal-IgG1), mPax6 (mouse monoclonal-IgG1/DSHB), 
Pax7 (mouse polyclonal-IgG1), mNeuN (mouse-IgG1/Chemicon), GFP (chicken 
polyclonal/Avian Labs), HA (rat polyclonal/Roche), Lim1/2 (mouse polyclonal-
IgG1/DHSB), c-Myc (rabbit polyclonal-Santa Cruz Biotechnology cat# scb-789), BrdU 
(rabbit polyclonal-Immunology Consultants Laboratory), and cngn2 (rabbit polyclonal).   
 
Double In situ/Immunolabeling in Fig. 2M-R and Fig. 6L-M was performed by 
sequentially performing a fluorescent in situ hybridization with cGLAST or cFGFR3 
followed by immuostaining with hNFIA antibody.  
 
Electroporation of chick embryos 
Expression constructs and the shRNAi cassettes were cloned into the avian retrovirus 
RCAS(B) vector (Morgan and Fekete, 1996). The RCAS expression constructs were 
injected into the embryonic chick spinal cord at stage HH13-15 (~E2) with the use of a 
capillary needle, micromanipulator, and dissecting microscope. Electroporation was 
carried out with a BTX Electro Square Porator (Momose et al., 1999). In co-
electroporation experiments, empty plasmid was utilized where necessary to ensure that 
equal concentrations of DNA were introduced during electroporation. In the BrdU pulse-
chase experiments, 250µl of a 1mg/ml BrdU-PBS solution was added directly to chick 
embryos at E5. Embryos were harvested 6 hours after the BrdU pulse.  
 
Culture and transfection of cortical progenitors  
Rat cortical progenitor cells were isolated via dissection of E13.5 rat embryonic cortex 
and dissociation with papain. Cells were plated at density of 2x104/ cm2 on plates coated 
with 15µg/ml of polyornithine (Sigma) and 1µg/ml human fibronectin (Biomedical 
Technologies). Cells were grown in DMEM/F12 supplemented with N2 and B27 
(GIBCO) and 20 ng/ml bFGF (R&D systems). Cells were expanded for 3-4 days before 
transfection. Cells were transfected with Lipofectamine 2000 using pCS+ or pcDNA 
plasmids containing GFP, HA-mNFIA, HA-mNFIB, and/or myc-mOlig2. Empty plasmid 
was added to bring the final total amount of DNA to 4µg where necessary. In 
experiments that required the removal of bFGF to promote astrocyte differentiation, 
bFGF was removed 24 hours post-transfection and replaced with media described above 
supplemented with 2% FCS. Transfected cells were scored on images captured with a 
Zeiss digital camera. 
 
Immunoprecipitation and Immunobloting 
Human embryonic kidney cells (HEK293) cells were transfected using calcium 
phosphate precipitation, with CMV-based expression plasmids containing myc-mOlig2 
and/or HA-mNFIA. Cells were harvested three days post transfection in a lysis buffer 
containing 100mM NaCl, 25mM Hepes pH 7.5, 5mM TritonX-100, 2mM KCl, and 
0.5mM PMSF. Cells were briefly sonicated and lysates were incubated overnight with 
agarose bead-conjugated antibodies to myc and HA; ProfoundTM HA and c-Myc Tag 
IP/Co-IP Kit (Pierce cat# 23610, 23620). Following incubation, beads were washed and 
incubated at 100oC to dissociate the beads from the IP-complexes. IP samples were run 
on an 8% polyacrylamide gel, transferred to nitrocellulose membranes, and 
immunoblotted with either c-myc or NFIA antibodies. Immunoblots were developed 
using ECL development reagent (Pierce cat# 32106). 
 
 Supplemental Figure S1. FACS plots and expression characteristics of various 
developmental markers with respect to NFIA. (S1A) FACS plots illustrating isolation 
of Olig2-GFP+/CD15-MMA+/PDGFRα- progenitors from E9.5 and E12.5 murine spinal 
cord. (S1B-D) Double Fluorescent in situ for NFIA and FGFR3.  (S1E-F) Double 
immunolabeling for NFIA and Lim1/2.  (S1F) Higher magnification image of the boxed 
region in (S1D).  Lim1/2+ (white arrowheads) and NFIA+ (yellow arrows) -expressing 
cells are distinct.  (S1G-I) cHes5 in situ hybridization and (S1J-L) cNFIA in situ 
hybridization on chick embryonic spinal cord.  Sections in (S1G-I) and (S1J-L) were 
processed in parallel and developed for the same length of time.   
  
Supplemental Figure S2. Ectopic overexpression of NFIA or NFIB in the embryonic 
chick spinal cord does not effect the generation of oligodendrocyte precursors. 
Overexpression of NFIA (S2A-C) or NFIB (S2D-F) from embryos collected at E5-E7 did 
not influence the temporal or spatial expression patterns of oligodendrocyte precursor 
markers Olig2 (S2G-L) or PDGFRα (S2M-R).  Overexpression of NFIA or NFIB 
promotes the precocious migration of FGFR3+ APs (S2S-X) and FABP7+ (S2Y-Z) APs at 
E7.  The analysis presented is representative of at least four embryos from three 
independent electroporation experiments. 
 Supplemental Figure S3. RNAi knockdown of cNFIA leads to a reduction in the 
expression of VZ progenitor markers at E5 and E6. Imunostaining with Pax7 
counterstained with nuclear marker Topro-3 is indicated in S3A-E, K. Pax7 marker 
expression is unaffected at E4, E5, and in the presence of the cNFIA-shRNAi-mutant 
(S3A-D, K), however by E6 there is a significant decrease in the number of Pax7-
expressing cells, (S3E, K) in the presence of the cNFIA-shRNAi. (S3F-J, L) 
Immunostaining with Sox9 counterstained with Topro3 in regions dorsal to the pMN 
domain.  
 
Supplemental Figure S4. Co-electroporation of Hes or NotchICD/SuH with NFIA-
RNAi rescues loss of Pax6 expression.  (A-C) Immunostaining with Pax6 
counterstained with Topro3 on NFIA-RNAi+p35 (A), NFIA-RNAi+NotchICD/SuH (B) or 
NFIA-RNAi+Hes (C) -electroporated embryos. (D) Quantitative analysis presented is 
representative of at least five sections x three electroporated embryos for each condition.  
 
 
Supplemental Figure S5. NFI genes are derepressed in the absence of Olig2.  (A-D) 
Analysis in chick at cE10.  (A, B) Immunostaining for NFIA (A) or NFIB (B).  Arrows 
indicate presumptive migrating cells.  (C, D) Double-label in situ reveals co-expression 
of cNFIA with GLAST (C) and FGFR3 (D). (E-M) Double-immunolabeling for NFIA 
and Olig2-GFP, in Olig1/2 heterozygous (E-H), or homozygous (I-L), embryos.  Note 
increased proportion of double-positive cells in homozygotes (M).  Data are derived from 
four sections per embryo x 3 embryos of each genotype, from three different litters. 
 
